What future for Teva Oncology?

Discussion in 'Teva Oncology' started by anonymous, May 12, 2018 at 6:21 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    1. Specialty: Bendeka and Trisenox are dying a slow death as the patents run out, with Teva spending $0 on new trials, label expansions, etc.
    2. Biosimilars: we’re supposedly in this game, but the past two years Teva has spent peanuts on pre-launch and education, as opposed to the mega presence of Amgen, Genentech, Pfizer, etc, in Biosimilars.

    What will reps do a year from now.? They should have just sold off the business unit a year ago like they were threatening to.
     

  2. anonymous

    anonymous Guest

    Go away troll.
     
  3. anonymous

    anonymous Guest

    As a Teva Oncology escapee, wake up, all of you need to get out! Holding on for minor financial incentives to stay is a mistake, unless you are planning to retire. Teva Oncology is dead and the sales people who stay lack real recruit-ability. You are viewed as poor candidates for remaining part of a dying business unit.
     
  4. anonymous

    anonymous Guest

    Teva ONC reps already has dibs on internal positions. We all have opportunities to stay, which I'll be doing.
     
  5. anonymous

    anonymous Guest

    “Dibs”. Seriously? Who uses that expression? Are you competing to ride in the front seat of a car with your friends? You proved the point on recruit-ability. Your intelligence is a reflection of your statement above.
     
  6. anonymous

    anonymous Guest

    Btw Dibs is my ho mo sons boy toy. Dont use his name or I'll suck your schlong.
     
  7. anonymous

    anonymous Guest

    Last one out, turn out the lights!
     
  8. anonymous

    anonymous Guest

    That will be reserved for VPs that have a retention bonus. Everyone else is fucked as usual at Teva.
     
  9. anonymous

    anonymous Guest

    The lights have been off for a while now. Teva stopped paying bills because everyone has already left in every department. Nothing is being completed anymore or payment to vendors. What a shit show!
     
  10. anonymous

    anonymous Guest

    the Biosimilar you will get for Rituxan will be a mega blockbuster
     
  11. anonymous

    anonymous Guest

    You must be the same person that declared Synribo a game changer.
     
  12. anonymous

    anonymous Guest

    Not mentioned on the earnings call to revise guidance. Must be a micro blockbuster.
     
  13. anonymous

    anonymous Guest

     
  14. anonymous

    anonymous Guest

    Teva will put numerous resources and personnel into the Oncology franchise once they realize that they have an Oncology franchise.
     
  15. anonymous

    anonymous Guest

    Teva blows!
     
  16. anonymous

    anonymous Guest

    Do the goyim have senior positions at TEVA Oncology?